ABBOTINDIA

Abbott India's valuation metrics across multiple frameworks consistently point to an expensive entry point for fresh investors. The stock's current price of ₹26,994.65 represents a 24.85% decline from its 52-week high of ₹35,921.55, yet even at this corrected level, valuation multiples remain stretched. The trailing twelve-month P/E ratio of 38.73x places the stock in the "very expensive" category based on historical valuation bands, a designation it has maintained since October 2022 with brief interruptions. Enterprise value-based metrics reinforce the premium valuation thesis. EV/EBITDA of 31.49x and EV/EBIT of 32.82x significantly exceed pharmaceutical sector medians of approximately 18-22x EV/EBITDA. The EV/Sales multiple of 8.49x, whilst reflective of Abbott India's superior margins, appears demanding given the company's modest revenue growth trajectory. For context, faster-growing pharmaceutical companies with similar quality attributes typically trade at EV/Sales multiples of 5-7x.